Lupus preclinical platforms

Lupus preclinical platforms

Products & Services

Information

Biomedcode provides an advanced preclinical in vivo platform using a novel human IL23p19 transgenic mouse model of spontaneous lupus erythematosus, specifically designed for the evaluation of human therapeutics targeting fibrosis. Our platforms have a proven track record in assessing the preclinical efficacy of novel therapies, enabling researchers to accelerate the development of next-generation antifibrotic treatments with confidence.
Biomedcode Hellas SA
410
Biomedcode Hellas SA is a highly innovative preclinical CRO specializing in predictive humanized disease models for biologics development. We offer in vivo drug efficacy evaluation using a diverse array of proprietary mouse models carrying humanized targets such as TNF, TNFR1, IL17, IL23A, IL12B, RANKL, TL1A and others. Our models closely recapitulate the pathology and complexity of human diseases, including Rheumatoid Arthritis, Intestinal Inflammation, Interstitial Pulmonary Fibrosis, Systemic Sclerosis, Psoriasis, Osteoporosis, Lupus, Multiple Sclerosis, Cancer and more. We also provide ex vivo platforms for evaluating therapeutics targeting fibrosis and other complex pathways. Since 2006, we have partnered with over 130 pharmaceutical and biotech companies worldwide, supporting translational preclinical studies that de-risk programs, optimize decision-making, and accelerate IND-enabling studies. Combining extensive preclinical expertise with scientific consultation, custom solutions and an active R&D program, Biomedcode bridges discovery and clinical translation, helping teams advance innovative biologics with confidence.

Log in

See all the content and easy-to-use features by logging in or registering!